Xtant Medical Holdings Inc. reported its first-quarter 2025 financial results, showing a revenue increase of 18% year-over-year to $32.9 million. The company achieved a net income of $58,000, a significant turnaround from a net loss of $4.4 million in the same quarter of the previous year. The gross margin slightly decreased to 61.5% from 62.1% compared to the prior year's quarter. Adjusted EBITDA was reported at $3.0 million, a notable improvement from an adjusted EBITDA loss of $1.0 million in the previous year. Furthermore, Xtant Medical has updated its revenue guidance for the full year 2025, raising it to a range of $127 million to $131 million, reflecting an anticipated growth of 8% to 12% from its previous guidance of $126 million to $130 million. In terms of business developments, Xtant Medical launched Trivium™, a next-generation demineralized bone matrix allograft aimed at enhancing bone grafting procedures. The company also completed a secondary private sale of existing shares by OrbiMed Advisors LLC to several stockholders, led by Nantahala Capital Management LLC. Additionally, Xtant Medical terminated an investor rights agreement with OrbiMed, enabling greater flexibility in corporate governance.